ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has form...

Descripción completa

Detalles Bibliográficos
Autores principales: Fizazi, Karim, Albiges, Laurence, Loriot, Yohann, Massard, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2015
Materias:
Drug Profile
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554/
https://www.ncbi.nlm.nih.gov/pubmed/26313416
http://dx.doi.org/10.1586/14737140.2015.1081566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554/
https://www.ncbi.nlm.nih.gov/pubmed/26313416
http://dx.doi.org/10.1586/14737140.2015.1081566

Ejemplares similares